Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Neogenomics Inc (NASDAQ: NEO) was $12.40 for the day, down -13.97% from the previous closing price of $14.42. In other words, the price has decreased by -$13.97 from its previous closing price. On the day, 4.49 million shares were traded.
Ratios:
Our analysis of NEO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.89 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 0.67 whereas as Long-Term Debt/Eq ratio is at 0.44.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 15 ’24 when Olivo Alicia C sold 5,175 shares for $15.36 per share. The transaction valued at 79,475 led to the insider holds 37,129 shares of the business.
ALICIA OLIVO bought 5,175 shares of NEO for $81,713 on Nov 15 ’24. On Aug 15 ’24, another insider, Olivo Alicia C, who serves as the General Counsel of the company, sold 1,040 shares for $16.05 each. As a result, the insider received 16,695 and left with 43,813 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.41 while its Price-to-Book (P/B) ratio in mrq is 1.75.
Stock Price History:
Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $12.12. The 50-Day Moving Average of the stock is -20.86%, while the 200-Day Moving Average is calculated to be -18.06%.
Shares Statistics:
A total of 128.36M shares are outstanding, with a floating share count of 126.79M. Insiders hold about 1.22% of the company’s shares, while institutions hold 97.28% stake in the company.
Earnings Estimates
The company has 6.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.05, with high estimates of $0.06 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.19 and $0.1 for the fiscal current year, implying an average EPS of $0.16. EPS for the following year is $0.36, with 10.0 analysts recommending between $0.48 and $0.24.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $174.7M to a low estimate of $170.33M. As of the current estimate, Neogenomics Inc’s year-ago sales were $156.24MFor the next quarter, 10 analysts are estimating revenue of $182.24M. There is a high estimate of $184.87M for the next quarter, whereas the lowest estimate is $180M.
A total of 12 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $740.6M, while the lowest revenue estimate was $725.4M, resulting in an average revenue estimate of $735.63M. In the same quarter a year ago, actual revenue was $660.57MBased on 11 analysts’ estimates, the company’s revenue will be $812.21M in the next fiscal year. The high estimate is $829.54M and the low estimate is $770.03M.
